tert-Butyl 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiazol-2-yl)azetidine-1-carboxylate

Catalog No. :
ACHGKJ152
CAS No. :
2223049-14-5
Molecular Formula :
C17H27BN2O4S
Molecular Weight :
366.29

IUPAC Name:tert-butyl 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiazol-2-yl)azetidine-1-carboxylate

tert-Butyl 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiazol-2-yl)azetidine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiazol-2-yl)azetidine-1-carboxylate
IUPAC Nametert-butyl 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiazol-2-yl)azetidine-1-carboxylate
MDL No.MFCD31806153
Molecular FormulaC17H27BN2O4S
Molecular Weight366.29
SMILESO=C(N1CC(C2=NC(B3OC(C)(C)C(C)(C)O3)=CS2)C1)OC(C)(C)C
InChI KeyPEXOIHRJUAODIX-UHFFFAOYSA-N
Synonym1-Azetidinecarboxylic acid, 3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-thiazolyl]-, 1,1-dimethylethyl ester;2-(1-Boc-3-azetidinyl)thiazole-4-boronic Acid Pinacol Ester;tert-butyl 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiazol-2-yl)azetidine-1-carboxylate
CAS No.2223049-14-5

Synthetic Route by SureRoute

1. ACHGKJ152 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  4. Then
  5. ACHGKJ152 route product structure diagram
    ACHGKJ1522223049-14-5
Inquiry

2. ACHGKJ152 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACHGKJ152 route product structure diagram
    ACHGKJ1522223049-14-5
Inquiry

Comments (0)